Preprint Article Version 1 This version not peer reviewed

Pharmacokinetics and Tissue Distribution Kinetics of Puerarin in Rats Using Indirect Competitive ELISA

Version 1 : Received: 29 May 2017 / Approved: 30 May 2017 / Online: 30 May 2017 (07:47:09 CEST)

A peer-reviewed article of this Preprint also exists.

Kong, H.; Wang, X.; Shi, R.; Zhao, Y.; Cheng, J.; Yan, X.; Liu, X.; Wang, Y.; Zhang, M.; Wang, Q.; Qu, H. Pharmacokinetics and Tissue Distribution Kinetics of Puerarin in Rats Using Indirect Competitive ELISA. Molecules 2017, 22, 939. Kong, H.; Wang, X.; Shi, R.; Zhao, Y.; Cheng, J.; Yan, X.; Liu, X.; Wang, Y.; Zhang, M.; Wang, Q.; Qu, H. Pharmacokinetics and Tissue Distribution Kinetics of Puerarin in Rats Using Indirect Competitive ELISA. Molecules 2017, 22, 939.

Journal reference: Molecules 2017, 22, 939
DOI: 10.3390/molecules22060939

Abstract

Puerarin (PUE) is a compound isolated from the roots of Pueraria lobata. We studied the pharmacokinetics and tissue distribution kinetics of PUE in Sprague-Dawley rats following intraperitoneal administration of three concentrations. Indirect competitive ELISA based on an anti-PUE monoclonal antibody was used to determine the concentration of PUE in the blood, heart, liver, spleen, lung, kidney, hippocampus, cerebral cortex, and striatum. The plasma and tissue distribution kinetic characteristics following a single injection of PUE (20, 40, and 80 mg/kg) were calculated using a non-compartment model. In the high-dose (80 mg/kg) and medium-dose (40 mg/kg) groups, the kinetic profile of PUE in blood and kidney samples showed two absorption peaks, while that of the other tissues showed only one peak. In the low-dose (20 mg/kg) group, there was only one peak, irrespective of the sample type. Pharmacokinetic parameters such as the area under the curve, Cmax, and Tmax varied according to the administered dose. AUC and Cmax values increased dose-dependently. PUE was widely distributed in areas of the brain such as the hippocampus, cerebral cortex, and striatum, providing a foundation for guiding the use of PUE in the treatment of cerebral ischaemic stroke and neurodegenerative diseases.

Subject Areas

pharmacokinetics; tissue distribution; indirect competitive enzyme-linked immunosorbent assay; puerarin

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.